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INTRODUCTION
Ph, nn3colanccics i concemed with rhe ab orprion, disrribu-
tion and e1imin cion of dnlgl. The e factors, combined with
thc doslllg regimcn, derennine the magnitude and rime courOS'
of 3I1omicroblal concentrations in serum and [issue. Studies In
arumallllfecoon model, conducred in the latc 1940.1 and carly
1950~, Jemonsrratcd that in vivo activity ofbenzylpcmcillin IS
dcpendem primarily on the duration of rime that crul1l
c nccntraoons exceed the MI of the infecting pathogen II I.
More recem mldies have ob crved similar findings with
cephaJosporins 12,31. Th~ hort revIew on selected peets of
the pharrnacokllleci s of :lIlrlbiotlcs wdJ foeu on tho. e facrars
thar tmpact on the therapeutic aroviry of antibiotics. I wiU also
conUllcm on rhe role fphanmcokinetic, in the d '~e1opmenr
of landmark cephalo porins.
INTERSTITIAL FLUID AND TISSUE CONCENTRATIONS
Tu~ue Ilomogcnates have been the major mechod tor
(.'Som. tlng ris ue concentrations. However, thcrt: arc scveral
problem~ With thiS methodology, homogcll' tes mix
IIlrcrsoodl. intracellular and vascular cOll1p~nllenrs \ ithin any
given tI sue. In e rhe majoriry of bactcri~1 infections ~rc
extracellular, it IS thc intcrstiti~1 concemrations of ~ntibiotiC"
thar arc most 1ml'oreal)[. In general. erum concentration 3rc
berrcr predict rs of intersttrial (JUld on cntrations th. 11 arc
ti, suc horn gcn3te~. Thc ahiJlry I' drug to ac ulllul~tc
imra eUularly J. rgc1y dctcmlincs whcther ci sue hOlllogcnatcs
underestimate or overestimate inrerstio:ll drug concentration .
T. ble I lis the rntio of concentrations in blisrer fluid, white
blood ceLis ;lOd skelcClI muscle hOlllogenatc.."S to those in erum
for two ccphalosponns and two f1uoroquinolones 141. All our
drug; pr vldcd levels 111 blisrer fluid, model r IIIterstirial
£lUld. which were RO%-117% f tho e III senUll, n the other
hand, tissue hOl1logcnates for the two ceph 10 I' rins werc
only ,110/0-2.3% of erum concentrations. his resulted Irom
the diJuci n 0 Interstitial fluid level by the inrraceLiular Quid
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Table 1 Anllmicrobial penelration 1010 blister fluid. intracellular fluid
and skeletal muscle homogenates
AUC in fluid or tissue/AUC In serum
Drug Blister fluid Intracellular fluid" Mu cle tiSsue
Cef01l1xime 0.81 <0.01 0.15
Cefoxitln 0.80 0.04 0.11
Ciprofloxacln 117 6-7 3.6
Enoxacin 1.14 3.6-4 17
•Based on concentrations in neutrophils, Data obtaoned from [4J.
becaus' of the poor intracellul~rpenctration ofcephalosporins,
and eLle dilution of interstloal flUid levels by IIltracellular fJuld.
Tissue hOlllogcn:l[c concentrations of two fluoroqllinolones
were 1.7- to 3.6-fold bighcr lhan enUll on cnrrations
because of the very h.lgh intr:lcelluJar acclll11ubtion of this
class of antimicrobial.
The actual time course of intel'5tiriaI conccnrrati ns
compared wuh thosc ill senHn are dependent on the ratio of
lhe capillary diffllSing urfacc area ( A) to the volumc (V) of
lhe tluid [51. If eL,e ratio is vcry high, il1lerstinal c nc~'ntrarions
arc very imiJar to lh e in Cnlll1. Wound tluid nd
subcutancous fluid obt.ined trom impl~nted cotton threads
ace good III dels of inte . riri~l flUids with high A/V ratios. If
the raoo IS low, as would occur WIth fluid collections, therc IS a
lag in the cx hange 111 c 11 cntrntlons berween interstitial fluid
'and ('rum, This re ults III a peak concentrati JI th. t IS I wcr
and a trough concenrration that is higher III inteNtiri~1 fluid
than in sennJl. Figure 1 comp. res the concenrrations of
ceftriaxonc in crull!. blister /lui I and subcutaneously
implanted thre~ds III the 5.11l1e individuals [6J, hc lunges
in levels of Senlll1 and threads are very sim.iIOlr, while
concenrraci ns in blister fluid do not peak until h. The
di!fcren es in dmg level~ hetween serum and illt rstirial fluid,
Ill' ~ured by thread con entrari n. i rna t likcl)' due r the
high crum pr tcin binding of ceftriaxonc.
PHARMACOKINETIC EFFECTS OF SERUM PROTEIN BINDING
Protein hinding 15 another fa lor th t an play an imporranr
role in dercmuning the 011 cntr:\tion VS. tlme profile of an
~ntibi ti III interstitia.l Quid. Sin e anJy free unb Lind dmg
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Fig 1 Simultaneous concenlrallons of cehrlaxon III serum, blisler fluid
and subcutaneously Implanted threads followIng an ,nlmvonous dose.
Dnw obtained from [6 J
Illlllt'clll,'~ c, n ditTu,,' frolll ~l'rUIll through (apl1l, ry pores ltHO
Interstllul O\l1d, htgh hmdmg to en.nll protein.s sh uld resrnn
the o:ql1l.1Jbmllll bctween .l'rum and tis-sue. Redington, Ehen
and .raig 1-11 have pre\'lollSly shown that the rdaoonship
betwecn the area IInder the (OnCl'nrratlOlI-rime curve (AUC)
III serullI 311,1 bhsrer thud lor IH f{-bctanl annblotics W,l\ milch
Illon' hncar li)r tree dnlg rlun for rotal dnlg. H,lm teul :1I1d
Walder 171 have als\1 herved an lllvo:~e rebtIOJ\..\lllP between
protell1 hindillg ,111.1 n5\ II l' pelletr.nion. USlllg th,' AU : for
lOtal drug III 't'nllll an I IIltel'$tlliaJ tJllid, Thus, the free drug
conce1llranom In serum arc re,lsonable predl tor.. o( the timc
COu(\e of (ree drug concentr.ltlons in inrerstili:tl and Illany
ther body DUllk
The ther lllaJor phamlacokll1cnc et1~ct of serum protein
blndll1g t~ IhJI II' (all ,low the: diminanon of tlnlb'S dilllinatt'd
prill1anl. oy gIOl1\L'rubr iiltrati n IRI.
ThIS oecms becallse only free drug can fit lhrollgh lhe
c3ptlbry pores III the rt'nal ~olllerulu.. Most petll i1lll1s and
till' t'ady ccphalmponn are dlllllnalcd rella1ly, pnmarily by
tubular 't'creu II. Dnlg bindUlg to scrulIl protein dOL' not
appear to alter drug climlllatilln by thi me hanmll, Many of
lhe later cel'h"ll)~ponn , sud, :t..~ cefrnaxone, ccfott'tall and
ceftazidillle, h,wl' exceedingly I W fen:ll secretion cle,rance.
(less lhan 1_ IIIL/nun) and arc: elJllllnated pnntarily hy
~Iolllerui. r filtration 1':11 (Figure 2). The renal c1earan e of
these dnll,'S n1.Jrkedlv del'reases wlth Increased protem bmd1l1g
on the enlnl half-li\'es of two groups of ceph:llosporIlL. The
first group, depl IL'd by CIrcles, r"pre-scnt, eel halosportm wnh
high secretion clearance rates greatt'r lhan 100 mL/llIin. Evcn
thollgh all tht'. e c1n.I",'" are excreted pnmarily illlo 1mlie: ,
Increasing prOtell1 bll1dlng W:lS not a~so iated Witil nn change
In the St'nllll half-life. The second group, denoled by tnangles,
rcpn:scms dnJgs with very low secretion c1earance~ (Ie s than
12 nt.L/min). Incrcasmg serum prOtein bll1dmg of these dnlgs
was assoclatt'd WIlh an mcrt'ase in the elillllnatiOn of ha.l f-li fe in
senJnl. This varied frol11 , h:llf-hte of I.ll h r. I' ctrazidilllc
(17% prole-in blndlllg) to a half-life ofR h r. r eftriaxone (95%
High secretion
---6- Very low secretion
o
Fig 2 Rolmlonsh'lJ belw en se, urn proteon bindong and ellmonallon
11· If· life for cephalospOllns Wllh high soc,ellon clearanc rales (Circles)
and very low secret,on ,ale (Illangles) Data obtaoned from [9J
protclll bll1ding), efopcraznne allo has lllgh protem blmlmg
(1)(11)1,,) and a low renal ,c retion c1ear.m e, bUI I~ half-hfe IS
only 2 h. TillS I~ because lhe dnlg IS dll1lll1.ltcd pnmanly In the
Illle, r:Hher rhan by renal Illechanisms.
The eXlCIll of protem bllldmg of (L'phalosporulS does appear
to at eCI theIr blh.lry cxert'llon (H] Molt, war well::ht appears
to be rill' major detertlunant at biliary e, erenon f
ccphalosponns in bOlh a11ln1.11s am! 1I1.J1I. Drug< With
llIolenlbr \VL'lglm lcs~ thall 500. SUL'h as ·dot,l.ime alld
ceuzoximc, h.we 111inil1\~1 biltary l'xcrenon, wherea> cefoper-
~zont' has the hi~he>t molecular wcighl (646) alld L~ e1J11ul1aled
primarily in the bile, A\ shown m Table 2 for ccph'llosporlns
WIth molecular \Vel~hts in the range S( 0-6(1), bl.1Jary
t'xcrenon progressl ely Illcreascs a~ protem hllu:lmg mes from
17% to 23% (cdrnl IlIlle anu cefsulodm) to 9,"{, ( L"ftriaxolll')
PENETRATION INTO CSf
The penet , nOli of andbi n s mto tilt' SF difft' fr 1\1 othcr
sItes because of thc ab ellce of capiUary porc Jl1d the tight
junClioll5 berwe-en the endothelial cells [I OJ. lipid solubility,
tht' dcgrt'e of loni7~1tion. protem bllld.lllg and molecular tze
are :til f.1CtOrs lhat call alfect the paSs,1ge ofdrug< IOto the ·SF.
ll1ce Il-Ia OIllS arc weak , ids, they arc htgh.! IOllJzed at
physlOlo~cal pH and pcnetrate poorly mto non1l11tlamed • F.
All a ttvc transport PUIllP lhat transports pelllcllim and
Table 2 Relalionshlp belween bIliary excrellon and molecular welghl
and prolein binding ror four cephalospOllns
Molecular Protein Biliery
Drug weight binding excretion
Cehazldll1l0 545 17 MInImal
Moxalactam 521 53 Low
Ccfmonoxlm 511 77 Moderate
Cefotetan 574 85 Modorate
Cehriaxone 554 95 High
DSla obiS'" d hom [8J
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cdiria.'(onc from the blood imo the SF has been dcmonstl'3tcd
co ex.~ t tn n:rebl'3l capiUane [11.12]. H wever. th~ pump hilS
low capacIty and tr.msports very small quantjties 0 dnlg.
The: choroId plexus also cOlJCains an active transport pUll1p.
bur tM pump llIoves drugs, espeClally f3--la Cta illS. out of
the SF [131. The tr.HL~pon prorein II1volved in thL pUllIp
i~ the sallie prorein involved in renal tubular secretion. Thus,
tht, rate of renal rub.. s> rerion Illay predi r the relativc
r.lte f active tl'31 pon of. dru~ /Tom rhe ,·F. Table 3
delllonstT<ltes an inve e rdatioll5hip between the rate of renal
ruhul. r ,ccreOOIl and rhe I .. rcent 'SF penetrarion of our
cephalosponm a, rne<bured by rhe l'3tio of rhe AU in serum
ro tht: AU of unbound drug in senllll [4.14,151. As
menti lied earlier. some of the newer cephalo JlOrins. uch
as ccforaxil11c. bave vt:ry low renal ecretioll rates and
enhanced CSF penetration.
THERAPEUTIC SIGNIFICANCE OF PHARMACOKINETICS
SlOce the duration of exposure is the 01, jor detcnninant of
therapeutIC 1:111 acy of P-b ram antibIotics, the speed of drug
ebmination /Tom the body can be an imporralll derenninant of
the fi-equency of drug administratioll. In general. drugs with
half-bvL'S of an hour or les rcqULrl: doslOg Imervals of +-(, h,
whue rhose wHh half-lives from 2 co ·1 h can be aununlstert,d
at 8- to 12-h lI11ervals. T)ru With sh reer half-live, su h iIS
ccfo taxi lIle. Call also be admini tered rcl1ltively infrequently,
tbe dru!:: is qUite potel1t and h. s very low Ml for common
pathogens [161 nee-daily adminismcon should be po . iblc
for drugs wah half-lives over .J h.
. erum proteIn binding i kn Wll to reduce i/l vilm
antll1ucroblal a'tlvlty r17]. Its 1I11pacr on ill /Iill(l activity i.
more conrrovecsial. H wever, the prol nged serum half-lives
II1ducecl by protein binding for those eph losponm with
reduced rcnal clearance by tubular .se rerion may acrually
enwllce i" I/iv<) 311Umi'r bl,l cnvity. A recent study U'I the
rhigh-mfecrion Jll del WIth cefoniod supports tlu con cpt
[J 8J. The mVC5ogatO~clem n. r , ted that the extenr of protem
bmding of cc:fom id in mouse serUlll (76%) c uld be 111 l'L'aSCU
T ble 3 RelatIonshIp bctwe n CSF penetration and renal lubular
sacrelion fo' fOUl cephalospo"ns






'AUC drug in CSF/AUC of unbound drug In sorum Data Obta1ned
from (4.9.14,16J.
to oVl;:r 90% by till' intraperironeaJ injection of human
albunun. TIll lllcre; se ltl protein bin Iiug w, •. sso i, te I with
a longer half-life ~ncl a significant reduction in the amounr of
drug rcqultl.:d for efficacy with tWIce-daily do int::o hus.
prorl:lI bltlding co serum protcins for ccphalosporins by
glomerul~r filrranon can prOVIde a b..neficlal effecr by
illcrea~ing the half-life and maintaining the leveL~ abovc rh.,
MI for a prolonged duration. Thi..~ obvi usly contributed to
the 511 CC$ of ceL1Zolin among rhe variou. f]rst-gcnel'3tion
cepha.losporill5 and of cefrna.xonc among tile variollS
extended-spectrum cephalosponm.
Alrhough bllt ry excrerion provides a major p rhway for tht
elimination of ome antibi tics. the need f, r high amibioric
lo.:veh in bilc L, still cOlllroversiaI. Biliary .:xcretion . Iso
provides an altemati\·c roure for dnlg elimination in panent~
\vith impaIred renal function. For cephalosporins with
ignificanr biliary excretion. such as ccftriaxone and cetoper-
azone, lirtle if any do age modification IS n:qultl:d in panenes
with renal impairnlenr.
La.nly. the enhanced SF penctration of catJin ccphaJo,-
ponns, such iIS <'ftri. xone and efotaxiJlle, combined wirh
their ..nhanced poten y, 11:15 made these dr\l~ major agents for
the thel'3py of bacterial meni.ngitis and other N infections.
Some of tilt' enhaJlCed penetration may acrually represcl1t:
decreased clillllnation frol11 the F by tile choriod
plexu, pump.
CONCLUSIONS
olJccntraoolJS of free lnag 111 serum arc good predicrors 0
the time ourse of unboul1d drug III interstitial fluid. The
dumtinn of:lntibiotl expmurc l~ the important dcrenninanr of
i" I,i"" cfficacy of p-Iacram\, including the cephalosp rin. An
illcrea~e in protcill binding for drugs eliminated primarily by
.glomerular filtration wilJ increase the dmg half-life and
prolong rhe time for whIch :U1t1biotic level... exceed the MI
o rhe IIlfecrinl:'\ pathogen. 'unhermore, tile dual excrction of
~Olllt: f che c: dnt~ by both renal and biliary excred n lI1ak ~
oos, ge modi lcarion tmne e :lry in pacicn with eirher renal
or hepatic dy~unction. nle enh n cd N penel, tion of
~ol1le ephal sp rins ha.~ .l~o ncributed to their extensive USl'
in rhe trealmem f ba terial m ..ningitis. These pharmaco*
kinetic hange have contrihuted ro the ,u.: ess of landmark
ccphalosporins such as ccfrnaxone and cefot3xime.
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